Cyclo Therapeutics announces publication of positive data from phase II clinical study of Trappsol Cyclo for the treatment of Niemann
Cyclo Therapeutics, Inc. announced the publication of positive data from its Phase 1/II clinical trial, which demonstrated promising safety and efficacy results for Trappsol Cyclo in the treatment of Niemann-Pick Disease Type C1, a rare, genetic disease causing cholesterol accumulation in cells, leading to dysfunction of the liver, lung, spleen and brain and premature death